产品概述

Lyme borreliosis is a bacterial infection caused by the spirochete Borrelia Burgdorferi, Borrelia Afzelii and Borrelia Garinii and is the most vector-transmitted human disease in Europe. The spirochetal bacteria were first described and isolated in 1981 by Willi Burgdorfer in the tick Ixodes dammini in Montana (USA). The infection with Borrelia is characterized by a variety of clinical symptoms and can be divided into 3 stages: Stage 1, early dermatitis, appearing days or weeks after the infection. Clinical: erythema migrans. Stage 2, early disseminated infection, appears weeks to months after infection. Clinical: lymphocytic meningoradiculitis (Bannwarth's syndrome), neuroborreliosis. Stage 3, late disseminated infection, occurring up to years after infection. Clinical: chronic progressive encephalomyelitis, acrodermatitis chronica atrophicans (ACA), chronic arthritis. Antibiotic therapy is indicated in all stages of the disease. It shortens disease duration significantly, when instituted in stage 1. Diagnosis of the bacterial infection relies on the detection of specific IgG antibodies against Borrelia. To ensure diagnostic specificity, the Borrelia IgG ELISA microwell strips are coated with the following Borellia-specific recombinant antigens: p18: B. afzelii (pKo) p21 = OspC (outer surface protein C): B. burgdorferi s.s. (B31), B. garinii (20047) p100: B. afzelii (pKo) VlsE: fusion protein of different genospecies Many features of later infection are not specific to Lyme Borreliosis and occur in other conditions. The diagnosis of Lyme Borreliosis should be made only after careful evaluation of the patient´s clinical history, physical findings, laboratory evidence and exposure risk evaluation.